ImageneBio Inc
NASDAQ:IMABiotechnology
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
Volume 0.00M
Average 0.35M
IMA Dividends Paid
Cash distributed to shareholders as dividends.
ImageneBio IncNASDAQ: IMA
Dividends Paid · Q1 FY2026 · quarter ended Mar 2026
Dividends paid outflow grows to $0
Q1 FY2026 dividends paid was $0, compared with $0 a year earlier. Trailing-twelve-month dividends paid was $0.
Context
- Dividends paid amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Dividends paid increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly dividends paid holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Dividends Paid history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Dividends Paid | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Dividends Paid vs competitors
How IMA compares with its peers on the latest reported figures
- Peers report in different currencies, so dividends paid is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IMAImageneBio Inc | LTM Mar 2026 | $0 USD | — | — | — |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $0 USD | — | — | — |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| FY2025 | $0 USD | — | — | 0.0% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $0 USD | — | — | — |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding IMA) | — | — | — | 0.0% | |
Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.12M) | (68.77M) | (68.17M) | (49.23M) | (52.4M) |
| Depreciation & Amortization | 544K | 751K | 1.02M | 490K | 328K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.18M | 7.53M | 0 | 5.3M | 15.39M |
| Change in Working Capital | (33.03M) | (15.14M) | (21.67M) | (3.98M) | (19.19M) |
| Accounts Receivables | 361K | (291K) | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | (2.87M) | (1.17M) | (2.82M) |
| Other Working Capital | (33.39M) | (14.85M) | (18.8M) | (2.81M) | (16.37M) |
| Other Non-Cash Items | 1.17M | 1.52M | 9.07M | 1.42M | 8.02M |
| Operating Cash Flow | (60.25M) | (74.11M) | (79.74M) | (46M) | (47.84M) |
| Capital Expenditures | (1.76M) | (1.43M) | (414K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (5.22M) |
| Purchases of Investments | 0 | (216.34M) | (90.05M) | (88.3M) | (10.4M) |
| Sales of Investments | 0 | 118.49M | 154.61M | 60.46M | 9.8M |
| Other Investing Activities | 0 | 0 | 0 | (7.07M) | 0 |
| Investing Cash Flow | (1.76M) | (99.28M) | 64.14M | (34.9M) | (5.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 15M |
| Common Stock Issued | 131.3M | 0 | 37.56M | 0 | 65.84M |
| Common Stock Repurchased | 0 | 0 | (663K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 582K | 1.1M | 39.09M | 0 | 54.63M |
| Financing Cash Flow | 131.74M | 1.1M | 75.98M | 0 | 135.47M |
| Effect of Forex Changes | 0 | 0 | (406K) | 0 | 604K |
| Net Change in Cash | 69.73M | (172.3M) | 59.98M | (80.91M) | 82.41M |
| Free Cash Flow | (62.01M) | (75.54M) | (80.16M) | (46M) | (47.84M) |
ImageneBio Inc
NASDAQ:IMA
Intrinsic Alpha fair value
Locked
Current Price
$4.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.